United States: FDA Approves New Indication For AstraZeneca And Daiichi Sankyo's Cancer Drug ENHERTU - Goodwin Procter LLP

On April 5, the FDA granted accelerated approval to AstraZeneca and Daiichi Sankyo's ENHERTU (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.